Literature DB >> 25939441

MRI findings and pathological features in early-stage glioblastoma.

Makoto Ideguchi1, Koji Kajiwara, Hisaharu Goto, Kazutaka Sugimoto, Sadahiro Nomura, Eiji Ikeda, Michiyasu Suzuki.   

Abstract

Magnetic resonance imaging (MRI) is an important diagnostic tool for glioblastoma, with almost all cases showing characteristic imaging findings such as a heterogeneous-ring enhanced pattern associated with significant edema. However, MRI findings for early-stage glioblastoma are less clear. In this study, a retrospective review of MRI findings in five patients showed slight T2WI signal changes on initial scans that developed into typical imaging findings of a ring-like or heterogeneously enhanced bulky tumor within 6 months. The diagnoses based on initial MRI were low grade glioma in three cases, venous thrombosis in one case, and uncertain in one case. Four cases were treated with gross total resection, while one case underwent biopsy. Immunohistochemical examinations showed that two cases were p53-positive, and that all cases were IDH1 R132H-negative and had overexpression of EGFR. FISH analysis showed that all cases were 1p19q LOH-negative. De novo glioblastoma was the final diagnosis in all cases. Our results show that initial MRI findings in early-stage glioblastoma of small ill-defined T2WI hyperintense lesions with poor contrast develop to bulky mass lesions with typical findings for glioblastoma in as short a period as 2.5 months. The early MRI findings are difficult to distinguish from those for non-neoplastic conditions, including ischemic, degenerative or demyelinating processes. Thus, there is a need for proactive diagnosis of glioblastoma using short-interval MRI scans over several weeks, other imaging modalities, and biopsy or resection, particularly given the extremely poor prognosis of this disease.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25939441     DOI: 10.1007/s11060-015-1797-y

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  34 in total

1.  Glioblastoma detected at the initial stage in its developmental process -case report-.

Authors:  Hirofumi Oyama; Yusuke Ando; Shinichirou Aoki; Akira Kito; Hideki Maki; Kenichi Hattori; Kuniaki Tanahashi
Journal:  Neurol Med Chir (Tokyo)       Date:  2010       Impact factor: 1.742

2.  Prognostic significance of preoperative MRI scans in glioblastoma multiforme.

Authors:  M A Hammoud; R Sawaya; W Shi; P F Thall; N E Leeds
Journal:  J Neurooncol       Date:  1996-01       Impact factor: 4.130

3.  Evaluation of l-3-[123I]iodo-alpha-methyltyrosine SPET and [18F]fluorodeoxyglucose PET in the detection and grading of recurrences in patients pretreated for gliomas at follow-up: a comparative study with stereotactic biopsy.

Authors:  J B Bader; S Samnick; J R Moringlane; W Feiden; A Schaefer; S Kremp; C M Kirsch
Journal:  Eur J Nucl Med       Date:  1999-02

4.  MRI of high-grade astrocytic tumors: early appearance and evolution.

Authors:  K Okamoto; J Ito; N Takahashi; K Ishikawa; T Furusawa; S Tokiguchi; K Sakai
Journal:  Neuroradiology       Date:  2002-02-19       Impact factor: 2.804

Review 5.  Genetic pathways to primary and secondary glioblastoma.

Authors:  Hiroko Ohgaki; Paul Kleihues
Journal:  Am J Pathol       Date:  2007-05       Impact factor: 4.307

6.  Survival of patients with glioblastoma multiforme is not influenced by altered expression of p16, p53, EGFR, MDM2 or Bcl-2 genes.

Authors:  E W Newcomb; H Cohen; S R Lee; S K Bhalla; J Bloom; R L Hayes; D C Miller
Journal:  Brain Pathol       Date:  1998-10       Impact factor: 6.508

7.  DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma.

Authors:  H S Friedman; R E McLendon; T Kerby; M Dugan; S H Bigner; A J Henry; D M Ashley; J Krischer; S Lovell; K Rasheed; F Marchev; A J Seman; I Cokgor; J Rich; E Stewart; O M Colvin; J M Provenzale; D D Bigner; M M Haglund; A H Friedman; P L Modrich
Journal:  J Clin Oncol       Date:  1998-12       Impact factor: 44.544

8.  Cytogenetic analyses in 81 patients with brain gliomas: correlation with clinical outcome and morphological data.

Authors:  Filip Kramar; Zuzana Zemanova; Kyra Michalova; Libuse Babicka; Sarka Ransdorfova; Petr Hrabal; Petr Kozler
Journal:  J Neurooncol       Date:  2007-06-14       Impact factor: 4.130

9.  IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas.

Authors:  Takuya Watanabe; Sumihito Nobusawa; Paul Kleihues; Hiroko Ohgaki
Journal:  Am J Pathol       Date:  2009-02-26       Impact factor: 4.307

10.  Subtypes of oligodendroglioma defined by 1p,19q deletions, differ in the proportion of apoptotic cells but not in replication-licensed non-proliferating cells.

Authors:  S B Wharton; E Maltby; D A Jellinek; D Levy; N Atkey; S Hibberd; D Crimmins; K Stoeber; G H Williams
Journal:  Acta Neuropathol       Date:  2006-12-09       Impact factor: 17.088

View more
  16 in total

1.  A surgical strategy using a fusion image constructed from 11C-methionine PET, 18F-FDG-PET and MRI for glioma with no or minimum contrast enhancement.

Authors:  Makoto Ideguchi; Takafumi Nishizaki; Norio Ikeda; Tomomi Okamura; Yasue Tanaka; Natsumi Fujii; Machiko Ohno; Taichi Shimabukuro; Tokuhiro Kimura; Eiji Ikeda; Kazuyoshi Suga
Journal:  J Neurooncol       Date:  2018-03-07       Impact factor: 4.130

2.  Early-Stage Glioblastomas: MR Imaging-Based Classification and Imaging Evidence of Progressive Growth.

Authors:  C H Toh; M Castillo
Journal:  AJNR Am J Neuroradiol       Date:  2016-11-17       Impact factor: 3.825

3.  MR image-guided delivery of cisplatin-loaded brain-penetrating nanoparticles to invasive glioma with focused ultrasound.

Authors:  Kelsie F Timbie; Umara Afzal; Abhijit Date; Clark Zhang; Ji Song; G Wilson Miller; Jung Soo Suk; Justin Hanes; Richard J Price
Journal:  J Control Release       Date:  2017-03-11       Impact factor: 9.776

4.  Glioblastoma Multiforme with Hemorrhage Mimicking an Aneurysm: Lessons Learnt.

Authors:  Navneet Singla; Ashish Aggarwal; Sameer Vyas; Ankur Sanghvi; Pravin Salunke; Ravi Garg
Journal:  Ann Neurosci       Date:  2016-10-04

Review 5.  Standard clinical approaches and emerging modalities for glioblastoma imaging.

Authors:  Joshua D Bernstock; Sam E Gary; Neil Klinger; Pablo A Valdes; Walid Ibn Essayed; Hannah E Olsen; Gustavo Chagoya; Galal Elsayed; Daisuke Yamashita; Patrick Schuss; Florian A Gessler; Pier Paolo Peruzzi; Asim K Bag; Gregory K Friedman
Journal:  Neurooncol Adv       Date:  2022-05-26

6.  Early stage glioblastoma: retrospective multicentric analysis of clinical and radiological features.

Authors:  Isabella Ceravolo; Giovanni Barchetti; Francesco Biraschi; Carmela Gerace; Enrico Pampana; Alberto Pingi; Alessandro Stasolla
Journal:  Radiol Med       Date:  2021-08-02       Impact factor: 3.469

7.  Apparent diffusion coefficient for molecular subtyping of non-gadolinium-enhancing WHO grade II/III glioma: volumetric segmentation versus two-dimensional region of interest analysis.

Authors:  S C Thust; S Hassanein; S Bisdas; J H Rees; H Hyare; J A Maynard; S Brandner; C Tur; H R Jäger; T A Yousry; L Mancini
Journal:  Eur Radiol       Date:  2018-03-23       Impact factor: 5.315

8.  Diagnostic Performance of Arterial Spin Labeling for Grading Nonenhancing Astrocytic Tumors.

Authors:  Delgerdalai Khashbat; Masafumi Harada; Takashi Abe; Mungunbagana Ganbold; Seiji Iwamoto; Naoto Uyama; Saho Irahara; Youichi Otomi; Teruyoshi Kageji; Shinji Nagahiro
Journal:  Magn Reson Med Sci       Date:  2017-12-12       Impact factor: 2.471

9.  Glioblastoma Shortly after a Normal Conventional Brain Magnetic Resonance Imaging: A Report of Two Cases and Review of the Literature.

Authors:  Tayfun Hakan; Erhan Çelikoglu
Journal:  Asian J Neurosurg       Date:  2021-05-28

10.  Radioiodinated PARP1 tracers for glioblastoma imaging.

Authors:  Beatriz Salinas; Christopher P Irwin; Susanne Kossatz; Alexander Bolaender; Gabriela Chiosis; Nagavarakishore Pillarsetty; Wolfgang A Weber; Thomas Reiner
Journal:  EJNMMI Res       Date:  2015-09-04       Impact factor: 3.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.